Medical Supplies – Medical Products

March 16, 2009

Melengestrol acetate as a tool for inducing early ovulation in transitional mares

Filed under: Medicine and Dentistry — Tags: , — medical insurance @ 6:54 pm

Welcome to Wordpublish.org Body!

The efficacy of melengestrol acetate (MGA) to shorten the vernal transition of mares by synchronizing and accelerating the first ovulation of the year after 60 days of phototherapy was determined by ultrasonographic monitoring. A total of 16 mares in late transition were fed two doses of MGA (100 and 150 mg/mare/day) for 10 days. A luteolytic dose of prostaglandin was administered to each mare one day after the end of MGA treatment. The presence and duration of oestrus, follicular growth, uterine oedema and presence of ovulation were monitored by ultrasonography and the cervical tone was evaluated by rectal palpation. Results revealed that ovulation was detected in 87.5% of the mares treated with 150 mg MGA/mare/day for 10 days, while 62.5% in mares receiving 100 mg MGA/mare/day for 10 days. This was statistically different (P=0.03) from the untreated control mares which showed an ovulation rate of 20%. Mares that received 150 mg MGA/day for 10 days had a mean treatment to ovulation interval of 13.1+or-5.97 days after the end of treatment, while mares that received 100 mg MGA/day for 10 days had a mean of 25.6+or-10.50 days (P=0.01) to ovulation. It is concluded that MGA can be used for synchronizing and hastening the first ovulation of the year in mares.

Lopez-Bayghen, C. Zozaya, H. Ocampo, L. Brumbaugh, GW Sumano, H.
Department of Physiology and Pharmacology, Faculty of Veterinary Medicine and Zootechnics, National Autonomous University of Mexico (UNAM), Av. Universidad 3000, Coyoacan, Mexico City 04510, Mexico.

March 2, 2009

Pharmacokinetics and dosimetry of 188 Re-pharmaceuticals.

Filed under: Pharmacology, Toxicology and Pharmaceutical Science — Tags: , — medical insurance @ 10:35 pm

The main objective of this review is to apportion current and new insight into the biodistribution, radiopharmacokinetics, dosimetry and cell targeting of rhenium-188 labeled radiopharmaceuticals used as therapeutic drugs. The emphasis lies on the generator obtained rhenium-188, its physical, therapeutic, dosimetric and coordinated compounds. Its use in radioimmunotherapy for lymphoma and other hematological diseases with monoclonal antibodies is discussed. Radiolabeled peptides to target cell receptors are an important field in nuclear medicine and in some research facilities are already being used, especially, somatostatin, bombesin and other peptides. Small molecules labeled with 188 Re are promising as therapeutic drugs. A review about some of the non-specific targeting molecules with therapeutic or pain palliation effect such as phosphonates, lipiodol, microparticles and other interesting molecules is included. Research on the labeling of biomolecules with the versatile rhenium-188 has contributedto the development of therapeutics with favorable pharmacokinetic and dosimetric properties for cancer treatment.

Ferro-Flores,G Arteaga-de-Murphy,C
Gerencia de Aplicaciones Nucleares en la Salud, Instituto Nacional de Investigaciones Nucleares, Mexico.

Copyright 2009 Medical Paper & Medical Companies